MDxHealth (NASDAQ:MDXH) Posts Quarterly Earnings Results

Key Points

• MDxHealth reported a quarterly loss of ($0.15) earnings per share, which was below analysts' expectations of ($0.13).
• The company has updated its Q2 2025 guidance to a range of -0.150 to -0.150 EPS, indicating consistent losses ahead.
• MDxHealth stock saw a slight increase, trading at $2.49 with a market capitalization of $117.75 million and a negative PE ratio of -2.17.

MDxHealth (NASDAQ:MDXH - Get Free Report) posted its earnings results on Tuesday. The company reported ($0.15) earnings per share for the quarter, missing analysts' consensus estimates of ($0.13) by ($0.02), Zacks reports. MDxHealth had a negative return on equity of 492.11% and a negative net margin of 41.02%. MDxHealth updated its Q2 2025 guidance to -0.150--0.150 EPS.

MDxHealth Stock Performance

MDxHealth stock traded up $0.02 during mid-day trading on Tuesday, reaching $2.49. 115,605 shares of the company's stock were exchanged, compared to its average volume of 81,020. The firm has a market capitalization of $117.75 million, a PE ratio of -2.17 and a beta of 1.41. The business's fifty day simple moving average is $2.22 and its 200 day simple moving average is $1.90. The company has a quick ratio of 1.92, a current ratio of 2.00 and a debt-to-equity ratio of 13.81. MDxHealth has a one year low of $1.35 and a one year high of $3.50.

Wall Street Analyst Weigh In

MDXH has been the subject of several recent analyst reports. Wall Street Zen upgraded MDxHealth to a "hold" rating in a research report on Saturday, May 24th. Craig Hallum started coverage on MDxHealth in a research note on Thursday, July 17th. They issued a "buy" rating and a $8.00 price objective for the company.

MDxHealth Company Profile

MDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, Europe, and internationally. Its testing solutions includes Select mdx, a non-invasive urine test for prostate cancer that measures the expression of two mRNA cancer-related biomarkers; Confirm mdx for prostate cancer tissue test that validates epigenetic test that guides the detection of occult prostate cancer on a patient's previously biopsied negative tissue; and Resolved mdx for urinary tract infection that identifies personalized effective antibiotic options against the patient's infection.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.